Tofacitinib in juvenile idiopathic arthritis

Lancet. 2021 Nov 27;398(10315):1943-1945. doi: 10.1016/S0140-6736(21)01444-6. Epub 2021 Nov 9.

Authors

Sarah L N Clarke¹, Athimalaipet V Ramanan²

Affiliations

¹ MRC Integrative Epidemiology Unit and School of Population Health Sciences, University of Bristol, Bristol BS2 8BJ, UK; Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK.
² School of Translation Health Sciences, University of Bristol, Bristol BS2 8BJ, UK; Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK. Electronic address: a.ramanan@bristol.ac.uk.

PMID: 34767763
DOI: 10.1016/S0140-6736(21)01444-6

No abstract available

Publication types

Comment

MeSH terms

Arthritis, Juvenile* / drug therapy
Humans
Piperidines / therapeutic use
Pyrimidines / adverse effects

Substances

Piperidines
Pyrimidines
tofacitinib